Core Insights - Arch Biopartners Inc. has announced new findings identifying interleukin-32 (IL-32) as a novel cytokine associated with lipid droplets that may contribute to tubular injury and inflammation in diabetic kidney disease (DKD) [1][2][3] Research Findings - The research indicates that during DKD, kidney cells accumulate lipid droplets coated with IL-32, which is believed to drive kidney injury and inflammation [2] - IL-32 is described as a lipid droplet-associated cytokine that is upregulated during tubular injury, linking lipid dysregulation, inflammation, and progression in human DKD [3] Development Plans - Over the next 12–18 months, the company plans to conduct studies to support an Investigational New Drug (IND) application with the U.S. FDA, including in vivo proof-of-concept studies targeting IL-32 for DKD treatment [4] - Arch Biopartners aims to develop next-generation drug candidates targeting IL-32 to slow or prevent the progression of chronic kidney disease in patients with diabetes and related metabolic conditions [5] Current Treatment Landscape - Current treatments for diabetic kidney disease include SGLT2 inhibitors and GLP-1 receptor agonists, which provide cardiorenal benefits but are insufficient for many patients who continue to progress to kidney failure [6] - Arch's IL-32 drug development program is among the first to directly target metabolic dysregulation-associated inflammatory signaling within the kidney, representing a new pathway to address unmet needs in chronic kidney disease treatment [7] Company Overview - Arch Biopartners is a therapeutic biotech company focused on developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD), with a pipeline that includes treatments targeting inflammation and toxin-related kidney injury [9][10]

Core Insights - Vivoryon Therapeutics N.V. reported advancements in its clinical program for varoglutamstat, particularly in improving kidney function in diabetic patients, and successfully completed a capital raise to support its strategic objectives [2][3][4] Financial Results - Revenues for the nine months ended September 30, 2025, were zero, consistent with the same period in 2024 [10] - Research and development expenses decreased by EUR 8.9 million to EUR 3.7 million compared to EUR 12.6 million in the same period of 2024, primarily due to reduced clinical development costs [11] - General and administrative expenses were EUR 4.0 million, down from EUR 4.9 million in the previous year, attributed to lower personnel costs [12] - The net loss for the nine months ended September 30, 2025, was EUR 7.6 million, compared to EUR 17.1 million for the same period in 2024 [12] - Cash and cash equivalents as of September 30, 2025, were EUR 2.5 million, down from EUR 9.4 million at the end of 2024 [13] Clinical Program Updates - The Phase 2 program for varoglutamstat demonstrated statistically significant and clinically meaningful improvements in kidney function (eGFR) compared to placebo in two independent studies [4] - A new analysis indicated a consistent treatment effect across patients with varying eGFR baseline levels, particularly in those with more impaired kidney function [3][7] - The company plans to initiate a dedicated Phase 2b clinical study in patients with diabetic kidney disease (DKD) stage 3b/4, pending additional funding or partnerships [4][16] Corporate Development - Vivoryon successfully completed a private placement raising EUR 5.1 million, extending its cash runway into Q3 2026 [6][14] - The company is actively exploring additional funding and partnership opportunities to support its DKD program and other development initiatives [16] - A new CFO, Marcus Irsfeld, will succeed Anne Doering, who is stepping down in December 2025 [15]